Table 1

Diagnostic characteristics of multiple myeloma (MM) patients (modified from Shires and Wienand, 2016 [21]).

Patient No.	Age, sex	Disease subtype (Igk/Igl)^a)	Disease stage at diagnosis^b), CRAB features^c)	Treatment	Sampling period (mo)	% MAGEC1 cells at diagnosis in PB
Patient No.	Age, sex	Disease subtype (Igk/Igl)^a)	Disease stage at diagnosis^b), CRAB features^c)	Treatment	Sampling period (mo)	Total^e)	CD34+	CD19+	CD138+^f)
1	66, F	IgGl	2, RAB	Cyclophosphamide+dexamethasone, localized radiation	12^d)	1.29	0.71	0.46	0.12
2	80, M	IgAl	3, CRAB	Alternating between cyclophosphamide+dexamethasone and melphalan+prednisone	9^d)	1.35	0.43	0.52	0.41
3	73, F	IgGl	1, AB	Cyclophosphamide for one month, thereafter no myeloma treatment	24	1.82	0.86	0.86	0.22
4	73, F	IgGk	1, B	Melphalan+prednisone	24	1.99	1.00	0.93	0.06
6	33, M	IgGk	2, AB	Alternating between cyclophosphamide+dexamethasone and melphalan+prednisone	18^d)	1.15	0.59	0.43	0.13
7	66, M	IgGk	2, AB	Alternating between cyclophosphamide+prednisone and melphalan+prednisone, localized radiation	24	1.24	0.41	0.45	0.29
8	49, F	IgAk	3, RAB	Cyclophosphamide+dexamethasone as well as localized radiation	12^d)	1.46	0.42	0.75	0.26
9	83, F	IgGk	1, AB	Cyclophosphamide+prednisone as well as localized radiation	24	1.12	0.45	0.42	0.26
10	64, M	IgAk	2, AB	Cyclophosphamide+dexamethasone	6^d)	1.15	0.65	0.46	0.05
12	66, M	IgGk	2, RB	Localized radiation, cyclophosphamide+prednisone	6^d)	1.17	0.22	0.65	0.25

^a)Immunoglobulin G or A Lambda (Igl)/Kappa (Igk). ^b)ISS–International staging system (Greipp et al. 2005 [30]). ^c)Calcium >2.75 mmol/L; Renal: creatinine >90 mmol/L (F), >110 mmol/L (M); Anaemia: HB <12 g/dL (F), <13 g/dL (M); Bone lesions. ^d)Sampling period <24 months due to patient death. ^e)Calculated as the % of specific cells present in the mononuclear Ficoll preparation using flow cytometry, as previously described [21]. ^f)All MAGEC1-positive PC cells co-expressed ki-67, indicating proliferation potential [21].

Abbreviations: F, female; M, male.

Blood Res 2021;56:156~165 https://doi.org/10.5045/br.2021.2020335